Breaking News
July 15, 2018 - Parents who had severe trauma, stresses in childhood more likely to have kids with behavioral health problems
July 15, 2018 - At colloquium, a range of views on value of predictive algorithms | News Center
July 15, 2018 - Pittcon invites oral and poster presentations for 2019 Technical Program
July 15, 2018 - Virtual reality could offer psychotherapy for fear of heights, study shows
July 15, 2018 - Retooled vaccine raises hopes as a lower-cost treatment for Type 1 diabetes
July 15, 2018 - Kolon TissueGene To Start US Phase III Clinical Trial For Invossa
July 15, 2018 - Study finds prenatal marijuana use can affect infant size, behavior
July 15, 2018 - Howard Chang named HHMI investigator | News Center
July 15, 2018 - Study shows tailored mental health services improve wellbeing of emerging adults
July 15, 2018 - A bright future might help teens steer clear of violence
July 15, 2018 - Stanford Medicine magazine explores the art, science of listening and hearing | News Center
July 15, 2018 - New study tracks how the brain turns simple sensory inputs into meaningful categories
July 15, 2018 - Deadlier subtype of metastatic prostate cancer found to be common than previously thought
July 15, 2018 - UZH scientists identify enzyme that controls cell division
July 15, 2018 - Unhealthy Food Behaviors May Signal Eating Disorder in Teen
July 15, 2018 - Study raises doubts on a previous theory of Parkinson’s disease
July 15, 2018 - Grant awarded to study whether stem cells can treat urinary incontinence | News Center
July 15, 2018 - Imaging techniques may help assess immune system recovery in HIV patients
July 15, 2018 - Machine-learning may aid in diagnosis and treatment of mental health disorders
July 15, 2018 - ‘Skin Cancer, Take A Hike!’ program promotes sun safety and skin cancer awareness
July 15, 2018 - Blink Health announces lowest prices for generic prescriptions through Blue Eagle Health
July 15, 2018 - New drug strategy can alleviate multiple behavioral, cellular deficiencies in FXS mouse model
July 15, 2018 - Georgia State professor receives federal grant to study virus similar to Ebola virus
July 15, 2018 - Quitting Smoking? Even a Little Exercise Can Help You Stay Slim
July 15, 2018 - DBS treatment may slow the progression of Parkinson’s tremor in early-stage patients
July 15, 2018 - 5 Questions: Luby on virus with potential to cause global pandemic | News Center
July 15, 2018 - Corn loses its cancer-fighting phenolic acids when processed into cornflakes
July 15, 2018 - Study uncovers possible link between iron loading, alcohol intake and mortality
July 15, 2018 - Molecular insights of NagA enzyme could help combat TB
July 15, 2018 - The Facts on Tampons—and How to Use Them Safely
July 15, 2018 - Normalisation of ‘plus-size’ risks hidden danger of obesity, study finds
July 15, 2018 - $2.5 million award to support physician-scientist training | News Center
July 15, 2018 - Aeras announces publication of Phase 2 results of two TB vaccines
July 15, 2018 - Public to set research priorities in field of ethnic inequalities and severe mental illness
July 15, 2018 - Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months
July 15, 2018 - U.S. obesity rates rising again
July 15, 2018 - Millions could have incorrect statin, aspirin and blood pressure prescriptions | News Center
July 15, 2018 - Researchers identify factors associated with cell phone-related distracted driving in parents
July 15, 2018 - Bioethicists suggest ethical considerations for forensic use of genetic data
July 15, 2018 - Most clinical trial participants find benefits of sharing personal data outweigh risks, Stanford study finds | News Center
July 14, 2018 - Researchers solve protein puzzle that paves way for new cancer therapies
July 14, 2018 - Blood telomeres can help predict risk of disease worsening or death in COPD patients
July 14, 2018 - CDC: Nearly One-Third of Injury Deaths Occur at Home
July 14, 2018 - Injectable electronics offer powerful new tool in understanding how retinal cells work
July 14, 2018 - Human blood cells transformed into functional neurons | News Center
July 14, 2018 - Podcast: KHN’s ‘What the Health?’ ACA under fire. Again.
July 14, 2018 - Small device with motion sensors can predict older adults’ risk of falling
July 14, 2018 - Neurological Fallout From Ebola Infection Worse Than Thought
July 14, 2018 - Screening for impaired vision in older adults: New Canadian guideline
July 14, 2018 - Blood test for pregnant women can predict premature birth, Stanford-led study reports | News Center
July 14, 2018 - Study uncovers process that neutralizes tumor cells
July 14, 2018 - Four-protein biomarker blood test improves lung cancer risk assessment for smokers
July 14, 2018 - Researchers develop novel approach to bridge gap in cell-free systems
July 14, 2018 - Research reveals new gears in the circadian clock
July 14, 2018 - Researchers assess role of physician in preventing intimate partner violence perpetration
July 14, 2018 - Two diabetes medications don’t slow progression of type 2 diabetes in youth
July 14, 2018 - New clues to restoring fertility in women with disabling ovary disorder
July 14, 2018 - Compound in citrus oil could reduce dry mouth in head, neck cancer patients | News Center
July 14, 2018 - Streck ARM-D Kits detect more antibiotic resistance than comparable tests
July 14, 2018 - Study finds wide variations in follow-up imaging for women with non-metastatic breast cancer
July 14, 2018 - FDA expands its support for states to implement FSMA Produce Safety Rule
July 14, 2018 - CTI BioPharma Announces the Continuation without Modification of PAC203 Phase 2 Study of Pacritinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib
July 14, 2018 - First-hand accounts of premature baby loss inspires new resource
July 14, 2018 - Study identifies cellular ‘death code’ | News Center
July 14, 2018 - Federal judge enters consent decree against Minnesota dairy farm for selling adulterated meat
July 14, 2018 - New web-based game motivates people to exercise more
July 14, 2018 - Calcium electrotransfer could be used to target cancer cells, study finds
July 14, 2018 - Researchers identify new region in mouse brain that affects appetite and body weight
July 14, 2018 - Repeated testing produces ‘practice effect’ that obscures true cognitive decline
July 14, 2018 - Amgen And UCB Resubmit Biologics License Application (BLA) For Evenity (romosozumab) To The US FDA
July 14, 2018 - New research detects brain cell that improves learning
July 14, 2018 - Spirit, Inspiring Change award winners announced | News Center
July 14, 2018 - Opioid patients face several barriers to treatment, study finds
July 14, 2018 - Black adults more likely to develop high blood pressure by age of 55
July 14, 2018 - Insurers fall short in catching and reporting Medicaid fraud, inspectors find
July 14, 2018 - Scientists identify structural and functional differences in human immune-surveillance protein
July 14, 2018 - FDA Approves TPOXX (tecovirimat) as the First Drug for the Treatment of Smallpox
July 14, 2018 - Visual perceptual skills are updated by process similar to memory reconsolidation, study finds
July 14, 2018 - Big Data in Precision Health focuses on how to make technology work for patient care | News Center
July 14, 2018 - New technique measures how well cancer drugs reach their targets
Nosopharm and UIC reveal pharmacology of new class of antibiotics to combat drug resistance

Nosopharm and UIC reveal pharmacology of new class of antibiotics to combat drug resistance

image_pdfDownload PDFimage_print

Nosopharm, a company dedicated to the research and development of new anti-infective drugs, and the University of Illinois at Chicago (UIC) today announce the publication of a study in Molecular Cell on the mechanism of action of odilorhabdins, a new class of antibiotics to combat antibiotic resistance.

The antibiotic, first identified by Nosopharm, is unique and promising on two fronts: its unconventional source and its distinct way of killing bacteria, both of which suggest the compound may be effective at treating drug-resistant or hard to treat bacterial infections.

Called odilorhabdins, or ODLs, the antibiotics are produced by symbiotic bacteria found in soil-dwelling nematode worms that colonize insects for food. The bacteria help to kill the insect and, importantly, secrete the antibiotic to keep competing bacteria away. Until now, these nematode-associated bacteria and the antibiotics they make have been largely understudied.

The odilorhabdin program was launched by Nosopharm in 2011. To identify the antibiotic, Nosopharm’s researchers team screened eighty cultured strains of the bacteria for antimicrobial activity. They then isolated the active compounds, studied their chemical structures and their structure-activity relationships, investigated their pharmacology and engineered more potent derivatives.

The study, published in Molecular Cell, describes the new antibiotic and, for the first time, how it works. Nosopharm’s Maxime Gualtieri, UIC’s Alexander Mankin and Yury Polikanov are corresponding authors on the study and led the research on the antibiotic’s mechanism of action. They found that ODLs act on the ribosome – the molecular machine of individual cells that makes the proteins it needs to function – of bacterial cells.

“Novel classes of antibiotics like the odilorhabdins are very difficult to discover, but then very interesting to investigate”, said Maxime Gualtieri, co-founder and chief scientific officer of Nosopharm. “Our research at Nosopharm is focused on the understanding of the pharmacology of this new class, and the elucidation of their mode of action is a part of this work. We accumulated several early evidences that the bacterial translation was the target of the ODLs. At this point, we needed complementary scientific expertise to investigate much more in detail the mechanism of action of the molecules. This was the purpose of our collaboration with the UIC.”

“Like many clinically-useful antibiotics, ODLs work by targeting the ribosome,” said Yury Polikanov, assistant professor of biological sciences in the UIC College of Liberal Arts and Sciences, “But ODLs are unique because they bind to a place on the ribosome that has never been used by other known antibiotics.”

“When ODLs are introduced to the bacterial cells, they impact the reading ability of the ribosome and cause the ribosome to make mistakes when it creates new proteins,” said Alexander Mankin, director of the Center for Biomolecular Sciences in the UIC College of Pharmacy. “This miscoding corrupts the cell with flawed proteins and causes the bacterial cell to die.”

While many antibiotics can slow bacterial growth, Mankin says antibiotics that actually kill bacteria, called bactericidal antibiotics, are rare.  

“The bactericidal mechanism of ODLs and the fact that they bind to a site on the ribosome not exploited by any known antibiotic are very strong indicators that ODLs have the potential to treat infections that are unresponsive to other antibiotics,” said Mankin, who is also professor of medicinal chemistry and pharmacognosy in the UIC College of Pharmacy.

According to the World Health Organization, antimicrobial resistance is one of the biggest threats to global health today and a significant contributor to longer hospital stays, higher medical costs and increased mortality.

In France, the Nosopharm researchers tested the ODL compounds against bacterial pathogens, including many known to develop resistance.

“We found that the ODL compounds cured mice infected with several pathogenic bacteria and demonstrated activity against both Gram-negative and Gram-positive pathogens, notably including carbapenem-resistant Enterobacteriacae,” said co-corresponding author Maxime Gualtieri, co-founder and chief scientific officer of Nosopharm.

Carbapenem-resistant Enterobacteriacae, or CRE, are a family of germs that have high levels of resistance to antibiotics. One study suggests that CRE, which are the common culprits in bloodstream and surgical site infections, contribute to death in up to 50 percent of patients who become infected.

The researchers say this study is a testament to the growing trend of international and cross-disciplinary collaboration, which is needed to combat the growing and global threat of antibiotic resistance.

“As a biotech company, Nosopharm has to focus on the pharmaceutical development of the ODLs,” said Philippe Villain-Guillot, co-founder and chief executive officer of Nosopharm. “Collaborations with academia with renown expertise in antibiotics like the UIC team help us for this preclinical development and add credibility to the research”.

NOSO-502, the first clinical candidate of the odilhorhabdins, is the most advanced molecule in Nosopharm’s portfolio. The company plans to begin the first clinical trials in humans in 2020.

Source:

ANTIBIOTIC RESISTANCE : NOSOPHARM AND THE UNIVERSITY OF ILLINOIS AT CHICAGO DESCRIBE MECHANISM OF ACTION OF NEW CLASS OF ANTIBIOTICS IN MOLECULAR CELL

About author

Related Articles